Data as of Jan 23
 +0.03 / +1.92%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Oxigene, Inc. engages in the development of therapeutics to treat cancer and eye diseases. It offers anti-vascular drugs referred to as vascular disrupting agents. Its products include Zybrestat (fosbretabulin) and Zybrestat Topical. The company was founded in 1988 and is headquartered in South San Francisco, CA.

Contact Information

Oxigene, Inc.
701 Gateway Boulevard
South San Francisco California 94080
P:(650) 635-7000
Investor Relations:



Mutual fund holders4.42%
Other institutional15.16%
Individual stakeholders0.93%

Top Executives

David ChaplinPresident, Chief Executive Officer & Director
Barbara RichingChief Financial Officer & Vice President
Jai BalkissoonVice President-Clinical Development
Kathleen M. LeeVice President-Chemistry, Manufacturing & Controls
Ronald W. PeroFounding Member

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.